Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biogen Inc noted delayed uptake of its Alzheimer’s drug, Aduhelm, in the US, but said it continues to believe in the treatment’s long-term potential.
Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from aduhelm in the third quarter.
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...